Curis, Inc. (NASDAQ:CRIS) saw a large growth in short interest in the month of November. As of November 29th, there was short interest totalling 268,000 shares, a growth of 130.8% from the November 14th total of 116,100 shares. Based on an average trading volume of 245,100 shares, the short-interest ratio is presently 1.1 days. Approximately 1.0% of the company’s stock are sold short.
Institutional investors have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. bought a new stake in Curis during the 3rd quarter valued at $27,000. Morgan Stanley increased its stake in Curis by 155.6% during the 2nd quarter. Morgan Stanley now owns 19,564 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 11,911 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Curis during the 2nd quarter valued at $40,000. Cetera Advisor Networks LLC bought a new stake in Curis during the 2nd quarter valued at $42,000. Finally, BB&T Securities LLC increased its stake in Curis by 131.6% during the 3rd quarter. BB&T Securities LLC now owns 43,994 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors own 26.32% of the company’s stock.
Curis stock opened at $1.53 on Friday. Curis has a 12-month low of $0.66 and a 12-month high of $2.90. The firm’s fifty day moving average is $1.77 and its 200 day moving average is $1.92.
Separately, ValuEngine downgraded shares of Curis from a “hold” rating to a “sell” rating in a research report on Tuesday, December 3rd.
Curis Company Profile
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
See Also: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.